Dr. Katie Paul Friedman joined the Center for Computational Toxicology and Exposure (previously National Center for Computational Toxicology) in the Office of Research and Development at the US EPA in August 2016, where she is currently focused on application of new approach methodologies to chemical safety assessment, with additional interests in uncertainty in alternative and traditional toxicity information, endocrine bioactivity and developmental neurotoxicity prediction, and in vitro kinetics. Previously, Dr. Paul Friedman worked as a regulatory toxicologist at Bayer CropScience with specialties in neuro-, developmental and endocrine toxicity, and predictive toxicology. She has been actively involved in multi-stakeholder projects to develop adverse outcome pathways, alternative testing approaches, and the regulatory acceptance of new approach methodologies. Her laboratory background includes development of high-throughput screening assays, the combined use of myriad in vitro and in vivo approaches, including receptor-reporter and biochemical assays, primary hepatocyte cultures, and targeted animal testing paradigms, to investigate the human relevance of thyroid and metabolic adverse outcome pathways using probe chemicals. Dr. Paul Friedman received a Ph.D. in Toxicology (2011) from the University of North Carolina at Chapel Hill.